


Amendments to the Claims:

1-3. (Canceled).

4. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a safe and effective amount of the compound of formula I or the pharmaceutically acceptable salts thereof, wherein



Formula (I)

R₁ is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6;


R₂ is hydroxyl, sulfydryl, methylthio group, or ethylthio group at position 2, 3 or 4.

5. (Currently amended) The pharmaceutical composition according to claim 3 4 comprising 0.01-99% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

6. (Currently amended) A pharmaceutical composition according to claim 3 4, wherein the dosage form of the pharmaceutical composition is tablet, capsule, ampule or pill.

7. (Withdrawn) A method for producing the compound of formula I, comprising the steps of:

(a) in the presence of copper powder and anhydrous alkaline earth metal carbonate, reacting the compound of formula II and the compound of formula III at 160-200° C., thereby producing the compound of formula Ia;




wherein

R₁ is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6,

R₃ is --OCH₃, --SCH₃, --OC₂H₅ or --SC₂H₅ at position 2, 3 or 4, and

X is Cl, Br or I;

(b) reacting the compound of formula Ia and BBr₃ in an inert solvent at -10° C. to 15° C., thereby producing the compound of formula I:



wherein, R₁ and R₃ are defined as above, and R₂ is -OH or -SH.

8. (Withdrawn) A method for producing a pharmaceutical composition, comprising the steps of mixing the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 with a pharmaceutically acceptable carrier to produce a pharmaceutical composition comprising 0.01-99 wt % of the compound of formula I, on the basis of the total weight.

9. (Withdrawn) Use of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 in the manufacture of a medicament for preventing fibrosis.

10. (Withdrawn) A method for treating fibrosis diseases, comprising administering a safe and effective amount of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 to a subject in need thereof.

11. (New) The pharmaceutical composition according to claim 4, wherein R₁ is methyl, and R₂ is hydroxyl
12. (New) The pharmaceutical composition according to claim 4, wherein R₁ is methyl at position 5, and R₂ is hydroxyl at position 4.
13. (New) The pharmaceutical composition according to claim 4 further comprises one or more pharmaceutically acceptable carriers or excipients.
14. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered orally, intravenously, intramuscularly or subcutaneously.
15. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is orally administered.
16. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered by external use.
17. (New) The pharmaceutical composition according to claim 15, wherein the dosage form of the pharmaceutical composition is ointment, gel, or drug-containing rubber cement.
18. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered parenterally.
19. (New) The pharmaceutical composition according to claim 4 comprising 0.1-90% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.
20. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered at a dose of about 0.25-1000 mg/kg animal body weight per day.
21. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered at a dose of about 2-80 mg/kg animal body weight per day.
22. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered in 2-4 separated dosages per day, or in the form of slow release.

23. (New) The pharmaceutical composition according to claim 13, wherein said carrier comprises a solid carrier selected from the group consisting of starch, lactin, dicalcium phosphate, microcrystalline cellulose, sucrose and white bole.

24. (New) The pharmaceutical composition according to claim 13, wherein said carrier comprises a liquid carrier selected from the group consisting of sterile water, polyethylene glycol, nonionic surfactant and edible oil.

25. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition comprises an adjuvant selected from the group consisting of a flavoring agent, colorant, preservative and antioxidant such as vitamin E, vitamin C, BHT and BHA.